Glucocerebrosidase level in the cerebrospinal fluid during enzyme replacement therapy--unsuccessful treatment of the neurological abnormality in type 2 Gaucher disease.
Migita
Makoto
M
Department of Paediatrics, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan, Japan.|Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, Japan, Japan.
Hamada
Hisamitsu
H
Department of Paediatrics, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan, Japan.
Fujimura
Juri
J
Department of Paediatrics, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan, Japan.
Watanabe
Atsushi
A
Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, Japan, Japan.
Shimada
Takashi
T
Department of Biochemistry and Molecular Biology, Nippon Medical School, Tokyo, Japan, Japan.
Fukunaga
Yoshitaka
Y
Department of Paediatrics, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8602, Japan, Japan.
D005260:Female; D005776:Gaucher Disease / Q000188:drug therapy*; D005962:Glucosylceramidase / Q000008:administration & dosage / Q000097:blood / Q000134:cerebrospinal fluid* / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D017211:Treatment Failure
D011994:Recombinant Proteins; D005962:Glucosylceramidase; C090568:imiglucerase